Provided are methods for treating inflammation in subject in need thereof. In some embodiments, the methods include administering to the subject an effective amount of a Sigma-1 receptor (S1R) activity modulator to thereby treat inflammation in the subject. Also provided are pharmaceutical compositions that include an effective amount of a Sigma-1 receptor (S1R) activity modulator and uses of the pharmaceutical compositions to treat inflammation in a subject in need thereof.

An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating which includes at least one plasticizer, at least one film-forming agent and optionally at least one anti-sticking agent.

An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating which includes at least one plasticizer, at least one film-forming agent and optionally at least one anti-sticking agent.

Provided herein are perfusion fluids for enzymatically cleaving A-antigens from a donor organ, and methods, uses, associated therewith. In particular, the perfusion fluids comprise two enzymes, GalNAcDeacetylase and Galactosaminidase and the fluids may further comprise a buffered extracellular solution and/or a crowing agent. Furthermore, the compositions described herein were found to have activity at temperatures and pH levels suitable for cell viability.

Provided herein are methods to inhibit or disrupt a bio film comprising contacting the bio film with an agent that cleaves the Holliday junction (HJ) structure in the bio film.

Provided herein are methods to inhibit or disrupt a bio film comprising contacting the bio film with an agent that cleaves the Holliday junction (HJ) structure in the bio film.

Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA®, but require a lower concentration of FII are described herein.

Disclosed herein are compositions and methods for improving hemostasis in the treatment of bleeding disorders and reversal of anticoagulant activity. Effective ratios of prothrombin (FII) and activated factor X (FXa) for the treatment of bleeding disorders that are as efficacious as FEIBA®, but require a lower concentration of FII are described herein.

An oral fibrinolytic composition comprising the enzymes serrapeptase and nattokinase. The composition treats and/or may prevent fibrosis conditions and their related symptoms in animals, including humans. This composition may further comprise of one or more enzymes, bioflavonoids, vitamins, coenzymes, minerals, probiotics, prebiotics, herbs, excipients and/or combinations thereof. The composition may improve lung capacity, oxygen saturation, vigor, and/or lung function. It may further alleviate dyspnea, limitations and fear caused by dyspnea, cough, phlegm, fatigue, body pain, chest discomfort, anxiety, depression, loss of appetite, and/or respiratory disorders. The composition of serrapeptase and nattokinase and/or one or more additional component may improve immune health, sleep, health-related quality of life (HRQoL), social well-being, health status, mental health and/or exercise capacity. The present disclosure also provides a method for improving or reducing the frequency and severity of fibrosis and related symptoms in a subject having a fibrotic disease.

An oral fibrinolytic composition comprising the enzymes serrapeptase and nattokinase. The composition treats and/or may prevent fibrosis conditions and their related symptoms in animals, including humans. This composition may further comprise of one or more enzymes, bioflavonoids, vitamins, coenzymes, minerals, probiotics, prebiotics, herbs, excipients and/or combinations thereof. The composition may improve lung capacity, oxygen saturation, vigor, and/or lung function. It may further alleviate dyspnea, limitations and fear caused by dyspnea, cough, phlegm, fatigue, body pain, chest discomfort, anxiety, depression, loss of appetite, and/or respiratory disorders. The composition of serrapeptase and nattokinase and/or one or more additional component may improve immune health, sleep, health-related quality of life (HRQoL), social well-being, health status, mental health and/or exercise capacity. The present disclosure also provides a method for improving or reducing the frequency and severity of fibrosis and related symptoms in a subject having a fibrotic disease.